Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls.

Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls. Blood. 2012 Aug 09; 120(6):1202-9.

View in: PubMed

subject areas

Adult
Aged
Aged, 80 and over
Case-Control Studies
Clinical Trials, Phase I as Topic
Clinical Trials, Phase II as Topic
Clinical Trials, Phase III as Topic
Cohort Studies
Female
Follow-Up Studies
Humans
Janus Kinase 1
Janus Kinase 2
Male
Medication Adherence
Middle Aged
Nitriles
Primary Myelofibrosis
Protein Kinase Inhibitors
Pyrazoles
Pyrimidines
Randomized Controlled Trials as Topic
Survival Analysis
Survivors
Treatment Outcome

authors with profiles

HAGOP M KANTARJIAN
ZEEV ESTROV
JORGE E CORTES
SRDAN VERSTOVSEK
ELIAS JOSEPH JABBOUR
GAUTAM BORTHAKUR
TAPAN MAHENDRA KADIA